Allergic Contact Dermatitis from Formaldehyde Exposure
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Understanding Asthma
Understanding Asthma The Mount Sinai − National Jewish Health Respiratory Institute was formed by the nation’s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic medical center the Icahn School of Medicine at Mount Sinai in New York City. Combining the strengths of both organizations into an integrated Respiratory Institute brings together leading expertise in diagnosing and treating all forms of respiratory illness and lung disease, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and bronchiectasis. The Respiratory Institute is based in New York City on the campus of Mount Sinai. njhealth.org Understanding Asthma An educational health series from National Jewish Health IN THIS ISSUE What Is Asthma? 2 How Does Asthma Develop? 4 How Is Asthma Diagnosed? 5 What Are the Goals of Treatment? 7 How Is Asthma Managed? 7 What Things Make Asthma Worse and How Can You Control Them? 8 Nocturnal Asthma 18 Occupational Asthma 19 Medication Therapy 20 Monitoring Your Asthma 29 Using an Action Plan 33 Living with Asthma 34 Note: This information is provided to you as an educational service of National Jewish Health. It is not meant as a substitute for your own doctor. © Copyright 1998, revised 2014, 2018 National Jewish Health What Is Asthma? This booklet, prepared by National Jewish Health in Denver, is intended to provide information to people with asthma. Asthma is a chronic respiratory disease — sometimes worrisome and inconvenient — but a manageable condition. With proper understanding, good medical care and monitoring, you can keep asthma well controlled. That’s our treatment goal at National Jewish Health: to teach patients and families how to manage asthma, so that they can lead full and productive lives. -
Formaldehyde Test Kit Utility
HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Cutan Ocul Manuscript Author Toxicol. Author Manuscript Author manuscript; available in PMC 2019 June 01. Published in final edited form as: Cutan Ocul Toxicol. 2019 June ; 38(2): 112–117. doi:10.1080/15569527.2018.1471485. Undeclared Formaldehyde Levels in Patient Consumer Products: Formaldehyde Test Kit Utility Jason E. Ham1, Paul Siegel1,*, and Howard Maibach2 1Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV, USA 2Department of Dermatology, School of Medicine, University of California-San Francisco, San Francisco, CA, USA Abstract Formaldehyde allergic contact dermatitis (ACD) may be due to products with free formaldehyde or formaldehyde-releasing agents, however, assessment of formaldehyde levels in such products is infrequently conducted. The present study quantifies total releasable formaldehyde from “in-use” products associated with formaldehyde ACD and tests the utility of commercially available formaldehyde spot test kits. Personal care products from 2 patients with ACD to formaldehyde were initially screened at the clinic for formaldehyde using a formaldehyde spot test kit. Formaldehyde positive products were sent to the laboratory for confirmation by gas chromatography-mass spectrometry. In addition, 4 formaldehyde spot test kits were evaluated for potential utility in a clinical setting. Nine of the 10 formaldehyde spot test kit positive products obtained from formaldehyde allergic patients had formaldehyde with total releasable formaldehyde levels ranging from 5.4 to 269.4 μg/g. Of these, only 2 shampoos tested listed a formaldehyde-releasing agent in the ingredients or product literature. Subsequently, commercially available formaldehyde spot test kits were evaluated in the laboratory for ability to identify formaldehyde in personal care products. -
Finding Hazards
FINDING HAZARDS OSHA 11 Finding Hazards 1 Osha 11 Finding Hazards 2 FINDING HAZARDS Learning Objectives By the end of this lesson, students will be able to: • Define the term “job hazard” • Identify a variety of health and safety hazards found at typical worksites where young people are employed. • Locate various types of hazards in an actual workplace. Time Needed: 45 Minutes Materials Needed • Flipchart Paper • Markers (5 colors per student group) • PowerPoint Slides: #1: Job Hazards #2: Sample Hazard Map #3: Finding Hazards: Key Points • Appendix A handouts (Optional) Preparing To Teach This Lesson Before you present this lesson: 1. Obtain a flipchart and markers or use a chalkboard and chalk. 2. Locate slides #1-3 on your CD and review them. If necessary, copy onto transparencies. 3. For the Hazard Mapping activity, you will need flipchart paper and a set of five colored markers (black, red, green, blue, orange) for each small group. Detailed Instructor’s Notes A. Introduction: What is a job hazard? (15 minutes) 1. Remind the class that a job hazard is anything at work that can hurt you, either physically or mentally. Explain that some job hazards are very obvious, but others are not. In order to be better prepared to be safe on the job, it is necessary to be able to identify different types of hazards. Tell the class that hazards can be divided into four categories. Write the categories across the top of a piece of flipchart paper and show PowerPoint Slide #1, Job Hazards. • Safety hazards can cause immediate accidents and injuries. -
Prevention and Management of Occupational Dermatitis and Latex Allergy in a Healthcare Setting Policy
Prevention and Management of Occupational Dermatitis and Latex Allergy in a Healthcare Setting Policy V3.0 June 2020 Summary The aim of the policy is to: . protect individuals employed by the Royal Cornwall Hospitals Trust from developing skin conditions through exposure to potential irritants they may encounter whilst at work . describe the occupational health management of those who develop skin conditions . minimise the risks to patients and staff that may arise as a consequence of skin conditions developed by healthcare workers. Posts with specific responsibilities: . ward/departmental managers . individual staff . Occupational Health Service . Health and Safety Team . Infection Prevention and Control Team . Dermatology Department . Procurement Team . Health and Safety Committee. Key points in the document: . the risk of skin problems is increased in those who are exposed to agents through their work that can irritate or sensitise the skin. This can include frequent handwashing and the use of gloves in healthcare workers. Many of the exposures that place those working in a healthcare setting at increased risk are related to infection prevention and control requirements . background information for staff and managers regarding dermatitis and allergy . assessment forms . referral to Occupational Health . reporting of occupational dermatitis. Prevention and Management of Occupational Dermatitis and Latex Allergy in a Healthcare Setting Policy V3.0 Page 2 of 28 Table of Contents Summary ........................................................................................................................... -
Formaldehyde May Be Found in Cosmetic Products Even When Unlabelled
Open Med. 2015; 10: 323-328 Research Article Open Access Laura Malinauskiene*, Audra Blaziene, Anzelika Chomiciene, Marléne Isaksson Formaldehyde may be found in cosmetic products even when unlabelled Abstract: Concomitant contact allergy to formaldehyde reliable method for detecting formaldehyde presence in and formaldehyde-releasers remains common among cosmetic products. patients with allergic contact dermatitis. Concentration of free formaldehyde in cosmetic products within allowed Keywords: chromotropic acid; formaldehyde; formalde- limits have been shown to induce dermatitis from short- hyde-releaser; high-performance liquid chromatography term use on normal skin. DOI 10.1515/med-2015-0047 The aim of this study was to investigate the formalde- Received: February 2, 2015; accepted: May 28, 2015 hyde content of cosmetic products made in Lithuania. 42 samples were analysed with the chromotropic acid (CA) method for semi-quantitative formaldehyde deter- mination. These included 24 leave-on (e.g., creams, 1 Introduction lotions) and 18 rinse-off (e.g., shampoos, soaps) products. Formaldehyde is a well-documented contact allergen. Formaldehyde releasers were declared on the labels of 10 Over recent decades, the prevalence of contact allergy to products. No formaldehyde releaser was declared on the formaldehyde has been found to be 8-9% in the USA and label of the only face cream investigated, but levels of free 2-3% in European countries [1]. formaldehyde with the CA method was >40 mg/ml and Formaldehyde as such is very seldomly used in cosmetic when analysed with a high-performance liquid chromato- products anymore, but preservatives releasing formalde- graphic method – 532 ppm. According to the EU Cosmetic hyde in the presence of water are widely used in many directive, if the concentration of formaldehyde is above cosmetic products (e.g., shampoos, creams, etc.), topical 0.05% a cosmetic product must be labelled “contains medications and household products (e.g., dishwashing formaldehyde“. -
Nomination Background: N-(3-Chloroallyl)Hexaminium Chloride
• NATIONAL TOXICOLOGY PROGRAM EXECUTIVE SUMMARY OF SAFETY AND TOXICITY INFORMATION N-(3-CHLOROALLYL)HEXAMINIUM CHLORIDE CAS Number 4080-31-3 July 16, 1991 Submitted to: NATIONAL TOXICOLOGY PROGRAM Submitted by: Arthur D. Little, Inc. Chemical Evaluation Committee Draft Report • • TABLE OF CONTENTS Page L NOMINATION HISTORY AND REVIEW .................... 1 II. CHEMICAL AND PHYSICAL DATA ....................... 3 III. PRODUCTION/USE ................................... 5 IV. EXPOSURE/REGULATORY STATUS...................... .10 V. TOXICOLOGICAL EFFECTS ........................... .11 VI. STRUCTURE ACTIVITY RELATIONSHIPS ..................48 VII. REFERENCES ..................................... : . ......... 49 APPENDIX I, ON-LINE DATA BASES SEARCHED ............ .53 APPENDIX II, SAFETY INFORMATION.................... .54 1 ,, .• • • OVERVJEWl Nomination History: N-(3-Chloroallyl)hexaminium chloride was originally nominated for carcinogenicity testing by the National Cancer Institute (NCI) in 1980 with moderate priority. In March 1980, the Chemical Evaluation Committee (CEC) recommended carcinogenicity testing. Due to budgetary cutbacks in 1982, this compound was reevaluated and recommended for in vitro cytogenetics and chemical disposition testing by the CEC, and was selected for chemical disposition testing by the Executive Committee. The renomination of this chemical in 1984 by the NCI was based on potentialfor significant human exposure and concern that it may be carcinogenic due to structural considerations. This recent nomination was -
The Older Woman with Vulvar Itching and Burning Disclosures Old Adage
Disclosures The Older Woman with Vulvar Mark Spitzer, MD Itching and Burning Merck: Advisory Board, Speakers Bureau Mark Spitzer, MD QiagenQiagen:: Speakers Bureau Medical Director SABK: Stock ownership Center for Colposcopy Elsevier: Book Editor Lake Success, NY Old Adage Does this story sound familiar? A 62 year old woman complaining of vulvovaginal itching and without a discharge self treatstreats with OTC miconazole.miconazole. If the only tool in your tool Two weeks later the itching has improved slightly but now chest is a hammer, pretty she is burning. She sees her doctor who records in the chart that she is soon everyyggthing begins to complaining of itching/burning and tells her that she has a look like a nail. yeast infection and gives her teraconazole cream. The cream is cooling while she is using it but the burning persists If the only diagnoses you are aware of She calls her doctor but speaks only to the receptionist. She that cause vulvar symptoms are Candida, tells the receptionist that her yeast infection is not better yet. The doctor (who is busy), never gets on the phone but Trichomonas, BV and atrophy those are instructs the receptionist to call in another prescription for teraconazole but also for thrthreeee doses of oral fluconazole the only diagnoses you will make. and to tell the patient that it is a tough infection. A month later the patient is still not feeling well. She is using cold compresses on her vulva to help her sleep at night. She makes an appointment. The doctor tests for BV. -
So You Have Asthma
So You Have Asthma A GUIDE FOR PATIENTS AND THEIR FAMILIES So You Have Asthma A GUIDE FOR PATIENTS AND THEIR FAMILIES NIH Publication No. 13-5248 Originally Printed 2007 Revised March 2013 Contents Overview ...........................................................................................................................................................1 Introduction ....................................................................................................................................................3 Asthma—Some Basics ................................................................................................................................4 Why You? .........................................................................................................................................................6 How Does Asthma Make You Feel? ......................................................................................................8 How Do You Know if You Have Asthma? ...........................................................................................9 How To Control Your Asthma ................................................................................................................ 11 Your Asthma Management Partnership ................................................................................... 11 Your Written Asthma Action Plan ............................................................................................. 12 Your Asthma Medicines: How They Work and How To Take Them .......................... -
Ethyl Alcohol
Right to Know Hazardous Substance Fact Sheet Common Name: ETHYL ALCOHOL Synonyms: Alcohol; Methylcarbinol CAS Number: 64-17-5 Chemical Name: Ethanol RTK Substance Number: 0844 Date: March 2011 Revision: March 2016 DOT Number: UN 1170 Description and Use EMERGENCY RESPONDERS >>>> SEE LAST PAGE Ethyl Alcohol is a clear, colorless liquid with a wine-like odor. Hazard Summary It is used in alcoholic beverages, as a solvent, and in making Hazard Rating NJDHSS NFPA other chemicals. HEALTH - 2 FLAMMABILITY - 3 ODOR THRESHOLD = 84 ppm REACTIVITY - 0 Odor thresholds vary greatly. Do not rely on odor alone to determine potentially hazardous exposures. FLAMMABLE POISONOUS GASES ARE PRODUCED IN FIRE CONTAINERS MAY EXPLODE IN FIRE Hazard Rating Key: 0=minimal; 1=slight; 2=moderate; 3=serious; 4=severe Reasons for Citation Ethyl Alcohol can affect you when inhaled and by passing Ethyl Alcohol is on the Right to Know Hazardous through the skin. Substance List because it is cited by OSHA, ACGIH, DOT, High concentrations may damage the fetus. NIOSH, IARC, NFPA and EPA. Contact can irritate the skin and eyes. Prolonged or repeated This chemical is on the Special Health Hazard Substance exposure can cause drying and cracking of the skin with List. peeling, redness and itching. Inhaling Ethyl Alcohol can irritate the nose, throat and lungs. Exposure to Ethyl Alcohol can cause headache, drowsiness, nausea and vomiting, and unconsciousness. It can also affect concentration and vision. SEE GLOSSARY ON PAGE 5. Repeated high exposure may affect the liver and the nervous system. Ethyl Alcohol is a FLAMMABLE LIQUID and a FIRST AID DANGEROUS FIRE HAZARD. -
STUDENT MANUAL Basic Principles in Occupational Hygiene
STUDENT MANUAL Basic Principles in Occupational Hygiene July 2019 This course is offered by the Occupational Hygiene Training Association and available free of charge though the OHTA website ohtatraining.org. Copyright information This student manual is provided under the Creative Commons Attribution - NoDerivs licence agreement. It can only be reproduced in its entirety without change, unless with the prior written permission of OHTA. Occupational Hygiene Training Association, 5/6 Melbourne Business Court Millennium Way, Pride Park, Derby, DE24 8LZ Email: [email protected] TABLE OF CONTENTS ACKNOWLEDGEMENTS i 1 INTRODUCTION 1 1.1 HISTORY 3 1.2 THE IMPORTANCE OF OCCUPATIONAL HYGIENE 6 2 HUMAN PHYSIOLOGY AND INDUSTRIAL DISEASES 8 2.1 SKIN 8 2.1.1 Dermatitis 9 2.1.2 Physical damage 10 2.1.3 Biological agents 10 2.1.4 Cancer 11 2.1.5 Other effects 11 2.2 MUSCULOSKELETAL SYSTEM 11 2.3 NERVOUS SYSTEM 12 2.4 ENDOCRINE SYSTEM 14 2.5 THE CIRCULATORY SYSTEM 15 2.5.1 The blood 17 2.6 RESPIRATORY SYSTEM 18 2.7 THE GASTROINTESTINAL TRACT 21 2.8 THE LIVER 22 2.9 URINARY SYSTEM 23 2.10 THE EYE 23 3 FUNDAMENTALS OF TOXICOLOGY 25 3.1 INTRODUCTION 25 3.2 TERMS 25 3.3 BASIC CONCEPTS 26 3.3.1 Physical form 27 3.3.2 Dose 27 3.3.3 Route of entry / absorption 28 3.3.4 Metabolism 29 3.3.5 Excretion 29 3.3.6 Response to toxins 30 3.4 STAGES OF TOXICOLOGICAL EVALUATION 30 3.4.1 What adverse effects can a chemical cause? 30 3.4.2 Are the effects seen in animals relevant to man? 31 3.5 SAFETY DATA SHEETS 31 4 EXAMPLES OF HAZARDOUS SUBSTANCES / PROCESSES 33 -
Global Strategy for Asthma Management and Prevention, 2019. Available From
DISTRIBUTE OR COPY NOT DO MATERIAL- COPYRIGHTED ASTHMA MANAGEMENT AND PREVENTION GLOBAL STRATEGY FOR Updated 2019 9 Global Strategy for Asthma Management and Prevention (2019 update) DISTRIBUTE OR COPY NOT DO The reader acknowledges that this reportMATERIAL- is intended as an evidence-based asthma management strategy, for the use of health professionals and policy-makers. It is based, to the best of our knowledge, on current best evidence and medical knowledge and practice at the date of publication. When assessing and treating patients, health professionals are strongly advised to use their own professional judgment, and to take into account local or national regulations and guidelines. GINA cannot be held liable or responsible for inappropriate healthcare associated with the use of this document, including any use which is not in accordance with applicable local or national regulations or COPYRIGHTEDguidelines. This document should be cited as: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Available from: www.ginasthma.org 1 Table of contents Tables and figures ............................................................................................................................................................... 5 Preface ................................................................................................................................................................................. 7 Members of GINA committees (2018) ................................................................................................................................ -
Safety Assessment of Imidazolidinyl Urea As Used in Cosmetics
Safety Assessment of Imidazolidinyl Urea as Used in Cosmetics Status: Re-Review for Panel Review Release Date: May 10, 2019 Panel Meeting Date: June 6-7, 2019 The 2019 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Christina L. Burnett, Senior Scientific Analyst/Writer. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] Distributed for Comment Only -- Do Not Cite or Quote Commitment & Credibility since 1976 Memorandum To: CIR Expert Panel Members and Liaisons From: Christina Burnett, Senior Scientific Writer/Analyst Date: May 10, 2019 Subject: Re-Review of the Safety Assessment of Imidazolidinyl Urea Imidazolidinyl Urea was one of the first ingredients reviewed by the CIR Expert Panel, and the final safety assessment was published in 1980 with the conclusion “safe when incorporated in cosmetic products in amounts similar to those presently marketed” (imurea062019origrep). In 2001, after considering new studies and updated use data, the Panel determined to not re-open the safety assessment (imurea062019RR1sum). The minutes from the Panel deliberations of that re-review are included (imurea062019min_RR1). Minutes from the deliberations of the original review are unavailable.